Curriculum Vitae

Larry Mark Weisenthal
16512 Burke Lane
Huntington Beach, CA 92647

Born: April 17, 1947, Chicago, Illinois

Citizenship: USA

Undergraduate Education:

University of Louisville
Louisville, KY 1965-68
Undergraduate chemistry major
No degree - entered medical school after 3 years. Retroactively awarded "B.A. equivalent," following first year of Medical School, which allowed me to be admitted to a PhD program at the University of Michigan

Medical Education: University of Michigan
Ann Arbor, MI 1968-70, 1973-75
M.D. (1975)

Graduate Education: University of Michigan
Ann Arbor, MI 1969-74
Ph.D. Pharmacology (1974)
Laboratory of Raymond W. Ruddon, MD, PhD

Post Graduate Education:

Residency: Internal Medicine
University Hospital
Ann Arbor, MI 1975-77

Fellowship: Medical Oncology Clinical Associate
National Cancer Institute, Bethesda, MD
Medicine Branch/COP/DCT/NCI 1977-79

Post-Doctoral Research: NCI/NIH, Bethesda, MD:
Laboratory of Marc E. Lippman, MD 1978-79

Military Service: U.S. Public Health Service
Surgeon Grade (Lt. Commander)
Active duty: 1977-79
Inactive reserve: 1979-present

Positions:	Instructor (Pharmacology), University of Michigan, 1973-75
	Staff Physician, Section Hematology/Oncology, Veterans Administration Medical Center Long Beach, CA, 1979-1984
	Assistant Professor in Residence Department of Medicine University of California Irvine Irvine, CA 1979-1986
	Clinical Investigator Veterans Administration Central Office Career Development Program Long Beach, CA,1984-87
	Associate Professor in Residence Department of Medicine University of California Irvine Irvine, CA 1986-1987
	Associate Adjunct Professor Department of Medicine University of California Irvine Irvine, CA 1987-1991
	Founder, Founding Corporate Director, Laboratory Director, Vice-President for Scientific Affairs Oncotech, Inc., Irvine, CA, 1987 - Jan. 1992
Current Positions:	Medical and Laboratory Director
	Weisenthal Cancer Group, LLC Huntington Beach, CA Jan. 1992 - present
	Clinical Professor of Medicine Department of Medicine, Hematology/Oncology University of California, Irvine Irvine, CA 1992 - present
Certification Boards:	American Board of Internal Medicine, 1978 Certified, Medical Oncology, 1979
Medical License:	California (1979-present) G 041204
Government Service:	Advisory/Site Visit Committee for National Cancer Institute Cell Culture New Drug Screening Program, 1985-90
	Oncology Reviewer, Veterans Administration National Research Advisory Group, 1984-87
	Editorial Advisory Board, Journal of the National Cancer Institute, May,1992-1998

Bibliography:

Journal Articles

1. Weisenthal, LM, Hug, CC, Jr., Weisbrodt, NW, and Bass, P. Adrenergic mechanisms in the relaxation of guinea-pig taenia coli in vitro. J Pharmacol Exptl Therap 178:497, 1971.

2. Bartolini, A, Weisenthal, LM, and Domino, EF. Effect of photic stimulation on acetycholine release from cat cerebral cortex. J Neuropharmacol 11:113, 1972.

3. Weisenthal, LM and Ruddon, RW. Characterization of human leukemia and Burkitt lymphoma cells by their acidic nuclear protein profiles. Cancer Research 32:1009, 1972.

4. Weisenthal, LM and Ruddon, RW. Catabolism of nuclear proteins in control and phytohemagglutinin-stimulated human lymphocytes, leukemic leukocytes, and Burkitt lymphoma cells. Cancer Res 33:2923, 1973.

5. Ruddon, RW, Weisenthal, LM, Lundeen, DE, et al. Stimulation of mitogenesis in normal and leukemic human lymphocytes by divalent and tetravalent lima bean lectins. Proc Natl Acad Sci (USA) 71:1848, 1974.

6. Von Hoff, DD and Weisenthal, LM. In vitro methods for predicting patient response to chemotherapy. Adv Pharmacol Chemother 17:133, 1980.

7. Von Hoff, DD, Weisenthal, LM, Ihde, D, et al. Growth of lung cancer colonies from bronchoscopy washings. Cancer 48:400, 1981.

8. Weisenthal, LM. Treatment of small cell lung cancer-1981. Arch Intern Med 141:1499-1501, 1981.

9. Weisenthal, LM. In vitro assays in preclinical antineoplastic drug screening. Semin. Oncology 8:362-376, 1981.

10. Weisenthal, LM, Dill, PL, Kurnick, NB, and Lippman, ME. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res: 43:258-64, 1983.

11. Weisenthal, LM, Marsden, JA, Dill, PL, and Macaluso, CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res: 43:749-57, 1983.

12. Weisenthal, LM, Lalude, AO'T, Miller, JB. In vitro chemosensitivity of human bladder cancer. Cancer 51:1490-1496, 1983.

13. Weisenthal, LM. Human tumor stem cell assay. New Eng J Med 308:1478-79, 1983 (letter).

14. Reichert, CM, Weisenthal, LM, and Klein, HG. Delayed hemorrhage after percutaneous liver biopsy. J. Clin Gastroenterol 5:263-266, 1983.

15. Weisenthal, LM, Shoemaker, J, Marsden, JA, Dill, PL, Baker, J, and Moran, EM. In vitro chemosensitivity assay based on the concept of total tumor cell kill. Rec Results Cancer Res 94:161-173, 1984.

16. Weisenthal, LM and Lippman, ME. Clonogenic and non-clonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615-632, 1985.

17. Weiner, RS, Kramer, BS, Clamon, GH, Feld, R, Evans, W, Moran, EM, Blum, R, Weisenthal, LM, Pee, D, Hoffman, FA, and DeWys, WD. Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. J Clin Oncol, 3:949-957, 1985.

18. Brewer, LA, Weisenthal, LM, and Light, R. Lung cancer, in Spittell, JA (ed), Clinical Medicine, Vol. 5, New York, Harper and Rowe, 1985, pp. 1-27.

19. Weisenthal, LM, Dill, PL, Finklestein, JZ, Duarte, TE, and Baker, JA. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 70:1283-1295, 1986.

20. Weisenthal LM. Clones, dyes, nuclides, mouse kidneys and....virions: a new non-clonogenic assay for tumor chemosensitivity. Eur J Cancer Clin Oncol 23:9-12, 1987. (editorial)

21. Su, YZ, Duarte, TE, Dill, PL, and Weisenthal, LM. Selective enhancement by menadiol (Vitamin K3) of in vitro drug activity in human lymphatic neoplasms. Cancer Treat Rep 71:619-25, 1987.

22. Weisenthal, LM, Su, YZ, Duarte, TE, Dill, PL, and Nagourney, RN. Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C. Cancer Treat Rep 71:1239-1243, 1987.

23. Weisenthal, LM, Su, YZ, Duarte, TE, and Nagourney, RA. Non-clonogenic, in vitro assays for predicting sensitivity to cancer chemotherapy. Prog Clin Biol Res 276:75-92, 1988.

24. McGuire, WL, Kern, DH, Von Hoff, DD, and Weisenthal, LM. In vitro assays to predict drug sensitivity and drug resistance. Breast Cancer Res Treat 12:7-21, 1988.

25. Weisenthal, L.M., Nagourney, R.A., Kern, D.H., Boullier, B., Bosanquet, A.G., Dill, P.L., Messenger, J.C., and Moran, E.M. Approach to the clinical circumvention of drug resistance utilizing a non-clonogenic in vitro assay measuring the effects of drugs, radiation, and interleukin-II on largely non-dividing cells. Adv.Clin.Oncol., 1:91-111, 1989.

26. Weisenthal, L.M., Nagourney, R.A., Kanan, P.G., and Kern, D.H. Laboratory assays to predict response to cancer chemotherapy: After 35 years are they suitable for the clinic?. Adv.Clin.Oncol., 1:127-143, 1989.

27. Kurohara W, Colman M, Nagourney RA, Weisenthal LM, Swingle K, Redpath JL. Radiation response of cells from human tumor biopsies as assessed by a dye exclusion technique: a possible predictive assay. Int J Radiat Biol 56:767-70, 1989.

28. Kern, D.H. and Weisenthal, L.M. Thymidine incorporation assay: prediction of response probability as a function of tumor type. Adv.Clin.Oncol., 1:53-59, 1990.

29. Kern, D.H. and Weisenthal, L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay utilizing suprapharmacologic drug exposures. J. Natl. Cancer Inst., 82:582-88, 1990.

30. Boullier, B.A., Bosanquet, A.G., Weisenthal, L.M., and Nagourney, R.A. In vitro enhancement of doxorubicin, vincristine, and melphalan cytotoxicity against fresh human chronic lymphocytic leukaemia cells. Cancer Treat. Rev. 17 (Suppl. A):90-91, 1990.

31. Nagourney, RN, Messenger, JC, Kern, DH, and Weisenthal, LW. Ethacrynic acid potentiation of nitrogen mustard and doxorubicin in fresh cultures of human neoplasms, Cancer Chemother. Pharmacol. 26:318-322, 1990.

32. Weisenthal, LM, Nagourney, RN, and Kern, DH. Extreme drug resistance (EDR) can be accurately detected in fresh specimens of human breast cancer and has implications for adjuvant chemotherapy. In Salmon, SE (ed): Adjuvant Therapy of Cancer VI. W.B. Saunders Co., Philadelphia and London, 1990, pp. 339-348.

33. Weisenthal LM, Nagourney R, Moran EM,amd Kern DH/ (1991) Laboratory detection of drug resistance and extreme drug resistance, in Clinical Management of the Drug-resistant Cancer Patient: New Options in Clinical Oncology. Nagourney RA and Sheikh KM, eds. Long Beach, CA, Memorial Medical Center Foundation, p. 70-81.

34. Weisenthal, L.M., Dill, P.L., and Pearson, F.C. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst 83:37-42, 1991.

35. Weisenthal, L. M.(1991) Effect of prior chemotherapy on biologic response modifier activity. J. Natl. Cancer Inst. 83, 790-791 (letter).

36. Weisenthal, L. M.and Kern, D. H. (1991) Prediction of drug resistance in cancer chemotherapy: the Kern and DISC assays. Oncology (U.S.A.)5, 93-103.
37. Weisenthal, L.M. Predictive assays for drug and radiation resistance. In: Masters J. (ed.), Primary Cultures from Human Tumor Biopsies: A Handbook, Kluwer academic publishers, Dordrecht,The Netherlands, 1991, pp. 103-148.

38. Weisenthal, L. M. (1992) Antineoplastic drug screening belongs in the laboratory, not in the clinic. J. Natl. Cancer Inst. 84, 466-469 (editorial).

39. Weisenthal, L. M. (1992) Antineoplastic drug screening. J. Natl. Cancer Inst. 84, 1289-1290 (letter).

40. Wilbur, D. W.; Camacho, E. S.; Hilliard, D. A.; Dill, P. L.and Weisenthal, L. M. (1992) Chemotherapy of non-small cell lung cancer guided by an in vitro drug-resistance assay. A pilot study. Br. J Cancer 65, 27-32.

41. Nagourney, R. A.; Evans, S.; Su, Y. Z.; Messenger, J.; Dill, P.and Weisenthal, L. M. (1993) 2-Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br. J. Cancer 67, 10-14.

42. Weisenthal, L. M. (1993) Cell culture drug resistance assays for hematologic neoplasms based on the concept of total tumor cell kill. The Clinical Role of Drug Resistance Assays in Hematologic Neoplasms (Kaspers, G.J.L., Pieters, R., Twentyman, P.R., Weisenthal, L.M., and Veerman, A. J. P., eds) Harwood Academic publishers, Chur, Switzerland), pp. 415-432.

43. Weisenthal, L.M. (1994) Clinical correlations for cell culture assays based on the concept of total tumor cell kill. In Vitro Chemosensitivity testing in Gynecologic Malignancies and Breast Cancer (Koechli, O., ed), (Contrib Gynecol Obstet V.19) Karger, Basel, pp. 82-90.

44. Weisenthal, L. M. (1995) Fresh tumor, cell culture assays for breast cancer. Drug and Hormonal Resistance in Breast Cancer: Cellular and Molecular Mechanisms (Dickson, R. B. and Lippman, M.E.,eds), Ellis Horwood, New York and London, pp. 323 – 350.

45. Woolley PV, Gollin SM, Riskalla W, Finskelstein S, Stefanik DF, Riskalla L, Swaney WP, Weisenthal LM, and McKenna RJ Jr. Cytogenetics, immunostaining for fibroblast growth factors, p53 sequencing, and clinical features of two cases of cystosarcoma phyllodes. Mol Diagn 5:179-90, 2000.

46. Weisenthal LM. Controversy over paper on chemosensitivity testing. Oncology 16:864; 2002.

47. Weisenthal LM and Nygren P. Current status of cell culture drug resistance testing, 2002. Available at: http://weisenthal.org/oncol_t.htm Peer review available at: http://weisenthal.org/onc_rev.htm.

48. Weisenthal LM, Weisenthal CM, Smith ME, Sanchez CG, and Berglund RF. Platinum resistance determined by cell culture drug resistance testing (CCDRT) predicts for patient survival in ovarian cancer, 2003. Manuscript and peer reviews available at: http://weisenthal.org/w_ovarian_cp_toc.html.

49. Kubota T and Weisenthal, L. Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer 9:82-7. 2006.

50. Bosanquet AG, Nygren P, and Weisenthal LM. Cell culture drug resistance testing in leukemias and lymphomas. in Kaspers GJL, Coiffer B, Heinrich MC, and Estey EH (eds). Innovative leukemia and lymphoma therapy. October, 2006. Taylor & Francis Publishers, Ltd. London, UK.

51. Weisenthal, L. M. Patel,N., Rueff-Weisenthal, C. (2008). "Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood." J Intern Med 264(3): 275-287.

52. Weisenthal, Larry, Liu, Haddy, and Rueff-Weisenthal, Constance. Death of human tumor endothelial cells in vitro through a probable calcium-associated mechanism induced by bevacizumab and detected via a novel method. Available from Nature Precedings <http://hdl.handle.net/10101/npre.2010.4499.1> (2010)

Ph.D. Thesis

Weisenthal, LM. Content and catabolism of chromatin proteins in control and PHA-stimulated human lymphocytes, leukemic leukocytes, and Burkitt lymphoma cells. Ph.D. thesis, University Microfilms, Ann Arbor, MI, 1974.

Abstracts

1. Weisenthal, LM, Hug, CC, Jr., and Bass, P. Adrenergic mechanisms in the relaxation of guinea-pig taenia coli. Fed. Proc 29:550, 1970

2. Weisenthal, LM and Ruddon, RW. Content of acidic nuclear proteins in human leukemia cells, Burkitt lymphoblasts, and PHA-stimulated lymphocytes. Fed Proc 31:629, 1972

3. Weisenthal, LM and Ruddon, RW. Chromatin-associated protease activity in proliferating and non-proliferating human lymphoid cells. Proceedings of XIth Interntional Cancer Congress, Florence, Italy, 1974

4. Weisenthal, LM, Von Hoff, DD, Lippman, ME, and Becker, RO. Differentiation of neuroblastoma cells occurring within an electrical field system. Proc Am Assoc Cancer Res 20:252, 1979

5. Weisenthal, LM and Marsden, JA. A novel dye exclusion assay for predicting response to cancer chemotherapy. Proc Am Assoc Cancer Res 22:155, 1981

6. Weisenthal, LM, Marsden, JA, Malefatto, J and Dill, PL. Predicting response to cancer chemotherapy with novel dye exclusion assay. Proceedings of XIIth International Congress of Chemotherapy, Florence, Italy, 1981.

7. Weisenthal, LM, Dill, PL, Marsden, JA, and Campbell, CK. Comparison of 3 in vitro chemosensitivity assays: dye exclusion, autoradiograpy, and agar cloning. Proc Am Assoc Cancer Res 23:184, 1982

8. LaLude, AO'T, Miller, JB, and Weisenthal, LM. In vitro chemosensitivity of human bladder cancer*. Proceedings of the American Urological Association Annual Meeting, Kansas City, MO, 1982

9. Weisenthal, LM, Baker, JA, and Marsden, JA. Glucocorticoid sensitivity of human neoplasms measured with a novel dye exclusion assay. Proc Am Assoc Cancer Res 24: 665, 1983

10. Weisenthal, LM, Marsden, JA, Macaluso, CK, Dill, PL, and Moran, EM. A non-clonogenic chemosensitivity assay measuring cell kill in the entire population of tumor cells. Int J Cell Cloning 1:261-262, 1983

11. Weisenthal, LM, Marsden, JA, Baker, JA, and Finklestein, JZ. In vitro chemosensitivity of acute lymphocytic and non-lymphocytic leukemias. Proc Am Assoc Cancer Res 25:192, 1984.

12. Weisenthal, L, Finklestein, J, Marsden, J, Dill, P, Baker, J, Iyer, P, Kaneshiro, C, and Moran, E. Clinical correlations of chemosensitivity with a predictive dye exclusion assay in human neoplasms. Proc Am Assoc Cancer Res 26:369, 1985.

13. Wilbur, D, Camacho, E, Hilliard, D, and Weisenthal, LM. Chemosensitivity guided chemotherapy of non-small cell lung cancer: a pilot study using a dye exclusion assay. Proc Am Soc Clin Oncol 4:(abs), 1985.

14. Weisenthal, LM, Su, YZ, Dill, PL, Duarte, TE, and Baker, JA. Laboratory detection and circumvention of drug resistance in human lymphatic neoplasms. Proc Am Assoc Canc Res 27:393, 1986.

15. Wilbur, D, Camacho, E, Hilliard, D, and Weisenthal, LM. Chemosensitivity guided chemotherapy of non-small cell lung cancer. Updating a pilot study using a dye exclusion assay. Proc Am Soc Clin Oncol 5:179, 1986.

16. Dill, PL, Weisenthal, LM, Magadia, GS, Nagourney, RA and Baker, JA. The core biopsy cytocentrifuge technique: a superior method for the diagnostic evaluation of bone marrow specimens obtained as dry taps for dilute aspirates. Blood 68:197a, 1986.

17. Weisenthal, LM and Shaw, KR. Patterns of multidrug resistance in human non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 6:15, 1987.

18. Nagourney, RA, Weisenthal, LM, Dill, PL, Just, R, Fass, L, and Baker, J. Menadiol in combination with cytotoxic chemotherapiers; The feasibility for resistance modification in human cancer: A pilot study. Proc Am Soc Clin Oncol 6:35, 1987.

19. Lepri, E, Duarte, TE, and Weisenthal, LM. Phorbol ester perturbs drug resistance in human lymphatic neoplasms. Fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands, Abs. 3.14, 1986.

20. Nagourney, RA, Groncy, PK, Oseas, RS, Finklestein, JZ, and Weisenthal, LM. Glucocorticoid sensitivity assessed in vitro: a prognostic factor for relapse in childhood acute lymphoblastic leukemia. Proc ASCO, 7:185, 1988.

21. Moran, EM, Nagourney, RA, Ottenheimer, EJ, Mahutte, K, and Weisenthal, LM. Reversal of acquired drug resistance with lidocaine and verapamil: a phase I study. Proc Am Assoc Cancer Res 29:218, 1988.

22. Nagourney, R.A., Messenger, J.C., Kern, D.H., and Weisenthal, L.M. In vitro enhancement of doxorubicin and nitrogen mustard cytotoxicity in drug resistant human neoplasms by ethacrynic acid. Proc Am Assoc Cancer Res. 30:574, 1989.

23. Weisenthal, L.M., Dill, P.L., and Swingle, K.F. Clinical radiation sensitivity profiles of human neoplasms are reproduced by a short-term in vitro (DiSC) assay measuring cytotoxicity in the total (largely nondividing) tumor cell population following ultra- high dose, single-fraction radiation. Proc. Am. Assoc. Cancer Res., 30:401, 1989.

24. Lippman, ME, Weisenthal, LM, Paik, SM, Nagourney, RN, and Kern, DH. erbB-2 positive specimens from previously-untreated breast cancer patients have in vitro drug resistance profiles which resemble profiles of specimens from patients who have previously failed combination chemotherapy. Proc Am Soc Clin Oncol, 1990.

25. Nagourney, R.A., Weisenthal, L.M., and Kern, D.H. In vitro detection of high grade drug resistance in fresh specimens of human non-small cell lung cancer: rational selection of chemotherapy based upon patterns of high-grade drug resistance. Proc.Am.Assoc.Cancer Res., 31: 2137-2137, 1990.

26. Weisenthal, L.M., Dill, P.L., and Pearson, F.C. Prior chemotherapy treatment effect on in vitro tumor-specific activity of biologic response modifiers: ImuVert, interleukin-2, tumor necrosis factor, and alpha interferon. In: Rothenberg Mace (ed.), Combining Biologic Response Modifiers with Cytotoxics in the Treatment of Cancer, Bethesda, Maryland: National Cancer Institute, 1990.

27. Weisenthal, L.M., Dill, P.L., and Pearson, F.C. Tumor and patient-specific activity of biologic response modifiers (ImuVert, tumor necrosis factor, alpha-interferon) in fresh specimens of human neoplasms detected by a sensitive and specific in vitro assay. Proc.Am.Assoc.Cancer Res., 31: 299-299, 1990.

28. Weisenthal, L.; Dill, P.and Birkhofer, M. (1991) Accurate identification of disease-specific activity of antineoplastic agents with an in vitro fresh tumor assay measuring killing of largely non-dividing cells. Proc. Am Assoc. Cancer Res. 32, 384.

29. Weisenthal LM. Bayesian analysis of published clinical correlation data for the DISC and MTT assays in CLL, ALL, ANLL, NHL and multiple myeloma International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma. March 16, 1992, Amsterdam, The Netherlands, p. 25, 1992.

30. Nagourney RA, Evans S, Su YZ, Messenger J, Dill P, Weisenthal LM. 2-chlorodeoxyadenosine cross-resistance patterns in human hematologic tumors Proc Am Assoc Cancer Res; 33:A3050 1992.

31. Nagourney RA, Su YZ, Evans S, Dill P, Weisenthal LM Is cisplatin active in human hematologic neoplasms? Proc Am Assoc Cancer Res; 33:A3049 1992 Weisenthal LM, Dill PL. In vitro effects of interleukin-2 (IL2) on fresh human tumor cell cultures measured by the DISC assay Proc Am Assoc Cancer Res; 33:A3313 1992.

32. Nagourney RA and Weisenthal LM. Evidence that alkylator drug resistance is the most important mechanism for the failure of chemotherapy in high grade and intermediate grade non-Hodgkin's lymphomas. Proc Am Assoc Cancer Res 34:306, 1993.

33. Nagourney RA and Weisenthal LM. Dexamethasone-induced cell death in primary cultures of childhood ALL predicts survival: a prospective trial with 13 year follow-up. Leukemia 9:531, 1995.

34. Weisenthal, LM. Fludarabine is selectively toxic to small lymphocytes in mixed large and small cell non-Hodgkin's lymphoma. Proc ASCO 15:1315, 1996

35. Weisenthal, LM. Gefitinib-induced cell death in short term fresh tumor cultures predicts for long term patient survival in previously-treated non-small cell lung cancer. ASCO Proceedings, J Clin Oncol 24(18S):17117, 2006.

36. L.M. Weisenthal, D. J. Lee, N. Patel. Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures of breast cancer and other human neoplasms. ASCO Proceedings, 2008.

37. Weisenthal, LM. Correlation of long term survival in stage 4 colorectal cancer with results of fluorouracil activity in MTT cell culture assay. ASCO Proceedings, Abstract 367. 2009.

38. 3. Weisenthal, L. M. (2010). Antitumor and anti-microvascular effects of sorafenib in fresh human tumor culture in comparison with other putative tyrosine kinase inhibitors. J Clin Oncol 28, 2010 (suppl; abstr e13617)

39. Weisenthal, L., H. Liu, Rueff-Weisenthal, C. (2010). "Death of human tumor endothelial cells in vitro through a probable calcium-associated mechanism induced by bevacizumab and detected via a novel method." Nature Precedings 28 May 2010. http://precedings.nature.com/documents/4499/version/1.

40. Weisenthal, Larry . Endothelial Massive Calcium Accumulation Death (MCAD): Mechanism, Target, and Predictive Biomarker for Anti-Angiogenic Therapy. 13th international symposium on anti-angiogenic therapy: recent advances and future directions in basic and clinical cancer research. LaJolla, CA. February 2011 Available from Nature Precedings http://dx.doi.org/10.1038/npre.2011.6647.1

41. Larry Weisenthal, Summer Williamson, Cindy Brunschwiler, and Constance Rueff-Weisenthal,Bevacizumab-induced tumor calcifications can be elicited in glioblastoma microspheroid culture and represent massive calcium uptake death (MCAD) of tumor endothelial cells. 14th International Anti-Angiogenesis Symposium, LaJolla CA, Feb 2012. Available from Nature Precedings http://dx.doi.org/10.1038/npre.2012.7069.1 (2012).

42. Larry Weisenthal, Summer Williamson, Cindy Brunschweiler, and Constance Rueff-Weisenthal. Massive calcium accumulation death (MCAD) of endothelial cells as a putative mechanism for bevacizumab anti-angiogenesis and acquired resistance to bevacizumab http://weisenthalcancer.com, 4th International Anti-Angiogenesis Symposium, LaJolla CA, Feb 2013 (In Press).

Presentations and Lectures (partial)

1. Chemosensitivity Testing: looking behind and looking ahead. Invited lecture: Farrah Fawcett Symposium on Chemosensitivity Testing and Circulating Tumor Cells., 2011, Santa Monica, CA

2. Activity of cisplatin in triple-negative breast cancer in comparison to other cancer types in fresh tumor cell culture assay using a cell death endpoint, American Society of Clinical Oncology Breast Cancer Symposium, 2009, San Francisco, CA http://tinyurl.com/triple-neg-cp

3. Long term survival in metastatic colon cancer predicted by 5FU activity in MTT assay,. American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2009, San Francisco, CA Slide presentation at ASCO website: http://tinyurl.com/weisenthal-colon-5FU

4. Introduction to new cancer diagnostics: targeting "targeted" drugs in cancer treatment, Invited lecture: Studienmeeting der AG ovarialkarzinom (ovarian cancer clinical trials meeting). Charité - Universitätsmedizin 2009, Berlin, Germany, Video at: http://vimeo.com/7577309

5. Targeting "targeted" therapy: the curious case of individualized tumor response testing. Invited lecture: William Beaumont Hospital 18th Annual Symposium on Molecular Pathology: Clinical Applications of Genomic Medicine., 2009, Troy, Michigan

6. Cell culture assays for traditional and "targeted" therapy in cancer, Invited lecture, Symposium on Individualized Tumor Response Testing, 2008 Reykjavik, Iceland

7. Antivascular activity of lapatinib and bevacizumab in primary microcluster culture of breast cancer and other neoplasms, American Society of Clinical Oncology Breast Cancer Symposium, 2008, Washington, D.C. Slide presentation at ASCO website: http://tinyurl.com/weisenthal-breast-lapatinib

8. Targeting "targeted" drug therapy in cancer,, Invited research seminar. NCI Division of Cancer Treatment, 2008, National Cancer Institute at Frederick, Maryland

9. Individualized tumor response testing with cell culture assays, Invited lecture to Turkish Oncology Society, 2008, Istanbul, Turkey

10. Individualized pharmacotherapy with cell culture assays, Invited lecture: 41st Annual Meeting of European Society for Clinical Investigation, 2007 Uppsala, Sweden

11. Functional profiling with cell culture assays in cancer therapy, Plenary lecture: Biannual Research Symposium of National Cancer Institute of Thailand, 2007 Bangkok, Thailand

12. Functional profiling for traditional and targeted antineoplastic drugs, Invited lecture, Fifth International Symposium on Cancer Research and Therapy. 2006, Tokyo, Japan.

Patents

1. Method to Detect Endothelial Cell Massive Calcium Accumulation Death

Patent number: 8623613

Abstract: Stains that are specific for calcium ion are used to assess and predict the effects of various treatments on the viability of cell types contained in a sample, wherein said stain detects endothelial cells that have massive calcium accumulation death.

Type: Grant

Filed: April 13, 2011

Issued: January 7, 2014

Inventor: Larry M. Weisenthal

2. Microaggregates Including Endothelial Cells

Patent number: 8192949

Abstract: Microaggregates which mimic the native environment of cells contained in biopsied tissue are used to assess and predict the effects of various treatments on the viability of cell types contained in the microaggregate.

Type: Grant

Filed: December 15, 2006

Issued: June 5, 2012

Inventor: Larry M. Weisenthal

3. Method to Detect Endothelial Cell Massive Calcium Accumulation Death

Application number: 20110275115

Abstract: Stains that are specific for calcium ion are used to assess and predict the effects of various treatments on the viability of cell types contained in a sample, wherein said stain detects endothelial cells that have massive calcium accumulation death.

Type: Application

Filed: April 13, 2011

Issued: November 10, 2011

Inventor: Larry M. WEISENTHAL

4. Immunopotentiating Protocol for Chemotherapy-Responsive Tumors

Patent number: 5149527

Abstract: Immunopotentiating compositions which are useful in causing tumor necrosis and/or regression in subjects who have previously received successful therapy which destroys tumors and stimulates cytotoxic macrophages are described. The immunopotentiators are administered at a time when formation of macrophages specifically cytotoxic for the tumor have been generated by previous therapy.

Type: Grant

Filed: September 18, 1990

Issued: September 22, 1992

Assignee: Oncotech, Inc.

Inventor: Larry M. Weisenthal

5. Method for Detecting immune-mediated Cytotoxicity

Patent number: 4996145

Abstract: A method for detecting the sensitivity of tumor cells to immune effector substances by using an assay that distinguishes living tumor cells from dead cells in mixed populations of cells. Acquired resistance to immune effectors used in therapy may be determined and used to identify methods to circumvent such resistance using the method.

Type: Grant

Filed: October 27, 1987

Issued: February 26, 1991

Assignee: Oncotech Incorporated

Inventor: Larry M. Weisenthal